Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Women 18 to 24 years of age who agree to participate by signing an informed consent form prior to recruitment.~  * Girls 9 and 10 years of age whose father/mother/guardian signs the informed consent form to participate in the study.~Exclusion Criteria:~* • Prior administration of an anti-HPV vaccine~  * Pregnant women or women planning to get pregnant in the next 8 months.~ * Auto-immune diseases~ * Women with a history of Guillain Barré syndrome.~ * Prior administration of immunoglobulins and/or any blood product in the past 6 months before the study's first vaccine dose.

- Gender: FEMALE
- Minimum Age: 9 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- Tetravalent Vaccine (Type: ACTIVE_COMPARATOR): * Month 2 visit: May be scheduled on the appropriate month +/- 3 weeks.~* Month 6, 21, 60 and 61 visit (vaccination scheme 0, 2, 6): May be programmed on the appropriate month +/- 4 weeks.~* Month 7 and 61 visit (vaccination scheme 0, 6, 60): The time interval between the month 6/60 visit and the month 7/61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination
- Bivalent Vaccine (Type: ACTIVE_COMPARATOR): * Month 1 visit: May be scheduled 21 to 62 days after the Day 0 visit.~* Month 6 visit: May be scheduled 161 to 216 days after the Day 0 visit.~* Month 6 visit: The time interval between the month 6 visit and the month 7 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination.~* Month 21, 60 and 61 visit (vaccination scheme 0, 1, 6): May be scheduled on the appropriate month +/- 4 weeks.~* Month 61 (vaccination scheme 0, 6, 60) The time interval between the month 60 visit and the month 61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).